Publications (35)275.28 Total impact
-
Article: Diverging trends of chronic bronchitis and smoking habits between 1998 and 2010.
[show abstract] [hide abstract]
ABSTRACT: BACKGROUND: No study has been carried out on the time trend in the prevalence of chronic bronchitis (CB) in recent years, despite its clinical and epidemiological relevance. We evaluated the trend in CB prevalence during the past decade among young Italian adults. METHODS: A screening questionnaire was mailed to general population samples of 20--44 year-old subjects in two cross-sectional surveys: the Italian Study on Asthma in Young Adults (ISAYA) (1998/2000; n = 18,873, 9 centres) and the screening stage of the Gene Environment Interactions in Respiratory Diseases (GEIRD) study (2007/2010; n = 10,494, 7 centres). CB was defined as having cough and phlegm on most days for a minimum of 3 months a year and for at least 2 successive years. The prevalence rates and the risk ratios (RRs) for the association between CB and each potential predictor were adjusted for gender, age, season of response, type of contact, cumulative response rate, and centre. RESULTS: CB prevalence was 12.5% (95%CI: 12.1-12.9%) in 1998/2000 and 12.6% (95%CI: 11.7-13.7%) in 2007/2010; it increased among never smokers (from 7.6 to 9.1%, p = 0.003), current light smokers (<15 pack-years; from 15.1 to 18.6%, p < 0.001), and unemployed/retired subjects (from 14.3 to 19.1%, p = 0.001). In this decade, the prevalence of current smoking decreased (from 33.6 to 26.9%, p < 0.001), whereas the prevalence of unemployment/premature retirement (from 5.3 to 6.0%, p = 0.005), asthma (from 5.0 to 6.2%, p = 0.003), and allergic rhinitis (from 19.5 to 24.5%, p < 0.001) increased. In both 1998/2000 and 2007/2010, the likelihood of having CB was significantly higher for women, current smokers, asthmatic patients, and subjects with allergic rhinitis. During this period, the strength of the association between CB and current heavy smoking (>=15 pack-years) decreased (RR: from 4.82 to 3.57, p = 0.018), whereas it increased for unemployment/premature retirement (from 1.11 to 1.53, p = 0.019); no change was observed for gender, asthma, and allergic rhinitis. CONCLUSIONS: Despite the significant reduction in current smoking, CB prevalence did not vary among young Italian adults. The temporal pattern of CB prevalence can only be partly explained by the increase of unemployment/premature retirement, asthma and allergic rhinitis, and suggests that other factors could have played a role.Respiratory research 02/2013; 14(1):16. · 3.36 Impact Factor -
Article: Look for comorbidities, but don't forget lung function.
American Journal of Respiratory and Critical Care Medicine 02/2013; 187(3):328-9. · 11.08 Impact Factor -
Article: The Rapid FEV(1) Decline in Chronic Obstructive Pulmonary Disease Is Associated with Predominant Emphysema: A Longitudinal Study.
[show abstract] [hide abstract]
ABSTRACT: Abstract Background: Early identification of patients with COPD and prone to more rapid decline in lung function is of particular interest from both a prognostic and therapeutic point of view. The aim of this study was to identify the clinical, functional and imaging characteristics associated with the rapid FEV(1) decline in COPD. Methods: Between 2001 and 2005, 131 outpatients with moderate COPD in stable condition under maximum inhaled therapy underwent clinical interview, pulmonary function tests and HRCT imaging of the chest and were followed for at least 3 years. Results: Twenty-six percent of patients had emphysema detected visually using HRCT. The FEV(1) decline was 42 ± 66 mL/y in the total sample, 88 ± 76 mL/y among rapid decliners and 6 ± 54 mL/y among the other patients. In the univariable analysis, the decline of FEV(1) was positively associated with pack-years (p < 0.05), emphysema at HRCT (p < 0.001), RV (p < 0.05), FRC (p < 0.05), FEV(1) (p < 0.01) at baseline and with number of hospitalizations per year (p < 0.05) during the follow-up. Using multivariable analysis, the presence of emphysema proved to be an independent prognostic factor of rapid decline (p = 0.001). When emphysema was replaced by RV, the model still remained significant. Conclusions: The rapid decline in lung function may be identified by the presence of emphysema at HRCT or increased RV in patients with a long smoking history.COPD Journal of Chronic Obstructive Pulmonary Disease 12/2012; · 1.79 Impact Factor -
Article: Project PriMo: Sharing Principles and Practices of Bronchodilator Therapy Monitoring in COPD A Consensus Initiative for Optimizing Therapeutic Appropriateness among Italian Specialists.
[show abstract] [hide abstract]
ABSTRACT: BACKGROUND: Even after publication of the 2011 update of GOLD report, some fundamental questions in the management of COPD are still opened and remain unanswered and the lack of recommendations may weaken the applicability of these guidelines in everyday clinical practice. OBJECTIVE: To assess the level of consensus amongst Italian respirologists on different topics related to the diagnosis, monitoring and the role of bronchodilator therapy in COPD, by using the Delphi Technique. METHODS: A Delphi study was undertaken between July and November 2011, when two questionnaires were consecutively sent to a panel of experts to be answered anonymously. After each round, the data were aggregated at group level of question topics and structured feedback was given to the panel. RESULTS: Q1 was sent to 208 pulmonologists randomly selected from different Italian regions. The 132 respondents (63% of those initially selected) were from northern (53%), central (19%) and southern (28%) Italy. Q2 was sent to all the Q1 respondents, and a response was received from 110 of these (83%). The main topics that reached the pre-defined cut off for consensus (67% or more) were: a) bronchodilator therapy with long-acting bronchodilators could be beneficial in patients with airflow limitation even in the absence of symptoms, b) in patients not fully controlled with one long-acting bronchodilator, maximizing bronchodilation (i.e. adding another bronchodilator with a different mechanism of action) is the preferable option; and c) the use of ICSs as add on therapy should be considered in severe patients with frequent exacerbations. CONCLUSIONS: Italian specialists agree on several aspects of the diagnosis and treatment of COPD and expert opinion could support everyday decision process in the management of COPD.Pulmonary Pharmacology & Therapeutics 11/2012; · 2.80 Impact Factor -
Article: The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults.
[show abstract] [hide abstract]
ABSTRACT: Background: This study is aimed at providing a real-world evaluation of the economic cost of persistent asthma among European adults according to the degree of disease control [as defined by the 2006 Global Initiative for Asthma (GINA) guidelines]. Methods: A prevalence-based cost-of-illness study was carried out on 462 patients aged 30-54 years with persistent asthma (according to the 2002 GINA definition), who were identified in general population samples from 11 European countries and examined in clinical settings in the European Community Respiratory Health Survey II between 1999 and 2002. The cost estimates were computed from the societal perspective following the bottom-up approach on the basis of rates, wages and prices in 2004 (obtained at the national level from official sources), and were then converted to the 2010 values. Results: The mean total cost per patient was EUR 1,583 and was largely driven by indirect costs (i.e. lost working days and days with limited, not work-related activities 62.5%). The expected total cost in the population aged 30-54 years of the 11 European countries was EUR 4.3 billion (EUR 19.3 billion when extended to the whole European population aged from 15 to 64 years). The mean total cost per patient ranged from EUR 509 (controlled asthma) to EUR 2,281 (uncontrolled disease). Chronic cough or phlegm and having a high BMI significantly increased the individual total cost. Conclusions: Among European adults, the cost of persistent asthma drastically increases as disease control decreases. Therefore, substantial cost savings could be obtained through the proper management of adult patients in Europe.International Archives of Allergy and Immunology 09/2012; 160(1):93-101. · 2.40 Impact Factor -
Article: An answer to Leonardo Fabbri.
Respiratory medicine 03/2012; · 2.33 Impact Factor -
Article: Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort.
[show abstract] [hide abstract]
ABSTRACT: Although women with severe non-allergic asthma may represent a substantial proportion of adults with asthma in clinical practice, gender differences in the incidence of allergic and non-allergic asthma have been little investigated in the general population. Gender differences in asthma prevalence, reported diagnosis and incidence were investigated in 9091 men and women randomly selected from the general population and followed up after 8-10 years as part of the European Community Respiratory Health Survey. The protocol included assessment of bronchial responsiveness, IgE specific to four common allergens and skin tests to nine allergens. Asthma was 20% more frequent in women than in men over the age of 35 years. Possible under-diagnosis of asthma appeared to be particularly frequent among non-atopic individuals, but was as frequent in women as in men. The follow-up of subjects without asthma at baseline showed a higher incidence of asthma in women than in men (HR 1.94; 95% CI 1.40 to 2.68), which was not explained by differences in smoking, obesity or lung function. More than 60% of women and 30% of men with new-onset asthma were non-atopic. The incidence of non-allergic asthma was higher in women than in men throughout all the reproductive years (HR 3.51; 95% CI 2.21 to 5.58), whereas no gender difference was observed for the incidence of allergic asthma. This study shows that female sex is an independent risk factor for non-allergic asthma, and stresses the need for more careful assessment of possible non-allergic asthma in clinical practice, in men and women.Thorax 02/2012; 67(7):625-31. · 6.84 Impact Factor -
Article: The impact of cigarette smoking on asthma: a population-based international cohort study.
[show abstract] [hide abstract]
ABSTRACT: The prevalence rates of smoking in subjects with asthma have frequently been reported as similar to those in the general population; however, available data are not up-to-date. There is only limited and somewhat conflicting information on the long-term effects of smoking on health outcomes among population-based cohorts of subjects with asthma. We aimed to investigate changes in smoking habits and their effects on forced expiratory volume in 1 s (FEV(1)) in subjects with asthma in comparison with the rest of the population, focusing on the healthy smoker effect. We studied 9,092 subjects without asthma and 1,045 with asthma at baseline who participated in both the European Community Respiratory Health Survey I (20-44 years old in 1991-1993) and II (1999-2002). At follow-up, smoking was significantly less frequent among subjects with asthma than in the rest of the population (26 vs. 31%; p < 0.001). Subjects with asthma who were already ex-smokers at the beginning of the follow-up in the 1990 s had the highest mean asthma score (number of reported asthma-like symptoms, range 0-5), probably as a result of the healthy smoker effect (2.80 vs. 2.44 in never smokers, 2.19 in quitters and 2.24 in smokers; p < 0.001). The influence of smoking on FEV(1) decline did not depend on asthma status. Smokers had the highest proportion of subjects with chronic cough/phlegm (p < 0.01). One out of 4 subjects with asthma continues smoking and reports significantly more chronic cough and phlegm than never smokers and ex-smokers. This stresses the importance of smoking cessation in all patients with asthma, even in those with less severe asthma.International Archives of Allergy and Immunology 01/2012; 158(2):175-83. · 2.40 Impact Factor -
Article: Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
[show abstract] [hide abstract]
ABSTRACT: Evidence has been provided that high-dose indacaterol (300 μg) can reduce lung hyperinflation in moderate-to-severe chronic obstructive pulmonary disease (COPD). To study whether low-dose indacaterol (150 μg) also reduces lung hyperinflation in comparison with the recommended dose of tiotropium (18 μg) in moderate COPD. This was a multicenter, randomized, blinded, 3-period cross-over, placebo-controlled study. Spirometry and lung volumes were measured before and 30, 60, 120, 180 and 240 min after the administration of single-doses of indacaterol, tiotropium, or placebo. The primary end-point was the change in peak inspiratory capacity (IC). The area under the 4-h curve (AUC(0-4)) for IC, 1-s forced expiratory volume (FEV(1)) and forced vital capacity (FVC) were secondary variables. 49 patients completed the study. On average, peak IC and AUC(0-4) for IC were significantly greater after indacaterol than placebo by 177 mL (p = 0.007) and 142 mL (p = 0.001), respectively. Differences in peak IC and AUC(0-4) for IC between tiotropium and placebo were 120 mL (p = 0.07) and 85 mL (p = 0.052), respectively. Differences between indacaterol and tiotropium were statistically insignificant. Peak IC increased by >20% in 12 patients with indacaterol and 9 with tiotropium (p = 0.001), and by >30% in 8 patients with indacaterol and 3 with tiotropium (p = 0.001). The effects of indacaterol and tiotropium on FEV(1) and FVC were statistically significant vs placebo. Low-dose indacaterol has a bronchodilator effect that is similar to the recommended dose of tiotropium, but it is slightly superior in reducing lung hyperinflation. ClinicalTrials.gov number: NCT00999908.Respiratory medicine 01/2012; 106(1):84-90. · 2.33 Impact Factor -
Article: Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults.
[show abstract] [hide abstract]
ABSTRACT: Few studies have investigated the factors associated with the early inception of chronic obstructive pulmonary disease (COPD). We investigated COPD risk factors in an international cohort of young adults using different spirometric definitions of the disease. Methods: We studied 4,636 subjects without asthma who had prebronchodilator FEV(1)/FVC measured in the European Community Respiratory Health Survey both in 1991 to 1993 (when they were 20-44 yr old) and in 1999 to 2002. COPD was defined according to the Global Initiative for Chronic Obstructive Lung Disease fixed cut-off criterion (FEV(1)/FVC < 0.70), and two criteria based on the Quanjer and LuftiBus reference equations (FEV(1)/FVC less than lower limit of normal). COPD determinants were studied using two-level Poisson regression models. Measurements and Main COPD incidence ranged from 1.85 (lower limit of normal [Quanjer]) to 2.88 (Global Initiative for Chronic Obstructive Lung Disease) cases/1,000/yr. Although about half of the cases had smoked less than 20 pack-years, smoking was the main risk factor for COPD, and it accounted for 29 to 39% of the new cases during the follow-up. Airway hyperresponsiveness was the second strongest risk factor (15-17% of new cases). Other determinants were respiratory infections in childhood and a family history of asthma, whereas the role of sex, age, and of being underweight largely depended on the definition of COPD used. COPD may start early in life. Smoking prevention should be given the highest priority to reduce COPD occurrence. Airway hyperresponsiveness, a family history of asthma, and respiratory infections in childhood are other important determinants of COPD. We suggest the need for a definition of COPD that is not exclusively based on spirometry.American Journal of Respiratory and Critical Care Medicine 10/2010; 183(7):891-7. · 11.08 Impact Factor -
Article: HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis
[show abstract] [hide abstract]
ABSTRACT: Objective To investigate the role of high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs) in staging pulmonary involvement in juvenile systemic sclerosis (JSS).Methods Clinical charts of 17 JSS patients (pts) were reviewed and high-resolution CT (HRCT) scans and PFTs performed at first and last visit were examined. Forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC) and carbon monoxide diffusing capacity [DL(CO)] were measured (% pred. values) while HRCT changes were graded according to the Schurawitzki method (min–max score: 0–18).ResultsAt initial assessment, 10 pts (58.8%) had pulmonary involvement (HRCT score >0 and/or PFTs <80% pred. values). PTFs abnormalities were consistent with a restrictive defect, with low FEV1, FVC and DL(CO) values and normal FEV1/FVC ratio. At first visit HRCT scores were inversely correlated with FEV1 (r = −0.75; P = 0.02), FVC (r = −0.685; P = 0.035), and DL(CO) values (r = −0.71; P = 0.03), but not with the FEV1/FVC ratio (r = −0.36; P = 0.31). Stronger inverse correlations were detected at last visit (median time interval: 4.3 years; min–max: 1–10 years) between HRCT and FEV1 (r = −0.86; P = 0.002), FVC (r = −0.79; P = 0.009) and DL(CO) (r = −0.79; P = 0.009), but not with the FEV1/FVC ratio (r = −0.33; P = 0.35). Changes in HRCT scores between first and last visit were correlated with changes in FEV1 (r = −0.74; P = 0.02), FVC (r = −0.81; P = 0.007), but not in DL(CO) values (r = 0.07;P = 0.84). At the last visit, of the 10 pts with pulmonary involvement at initial assessment 5 showed worsening of lung involvement and 5 either no significant changes in PFTs and HRCT or mild improvement.ConclusionsPFTs, namely lung volumes, represent a reliable “monitoring” tool in children with JSS to identify pts that need to undergo an HRCT to rule out initial pulmonary involvement and to monitor the course of ILD over time. The weaker clinical value of DL(CO) may relate to poor lung function technique in some younger children. Pediatr Pulmonol. 2009; 44:1226–1234. © 2009 Wiley-Liss, Inc.Pediatric Pulmonology 11/2009; 44(12):1226 - 1234. · 2.53 Impact Factor -
Article: HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis.
[show abstract] [hide abstract]
ABSTRACT: To investigate the role of high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs) in staging pulmonary involvement in juvenile systemic sclerosis (JSS). Clinical charts of 17 JSS patients (pts) were reviewed and high-resolution CT (HRCT) scans and PFTs performed at first and last visit were examined. Forced expiratory volume in 1 sec (FEV(1)), forced vital capacity (FVC) and carbon monoxide diffusing capacity [DL(CO)] were measured (% pred. values) while HRCT changes were graded according to the Schurawitzki method (min-max score: 0-18). At initial assessment, 10 pts (58.8%) had pulmonary involvement (HRCT score >0 and/or PFTs <80% pred. values). PTFs abnormalities were consistent with a restrictive defect, with low FEV(1), FVC and DL(CO) values and normal FEV(1)/FVC ratio. At first visit HRCT scores were inversely correlated with FEV(1) (r = -0.75; P = 0.02), FVC (r = -0.685; P = 0.035), and DL(CO) values (r = -0.71; P = 0.03), but not with the FEV(1)/FVC ratio (r = -0.36; P = 0.31). Stronger inverse correlations were detected at last visit (median time interval: 4.3 years; min-max: 1-10 years) between HRCT and FEV(1) (r = -0.86; P = 0.002), FVC (r = -0.79; P = 0.009) and DL(CO) (r = -0.79; P = 0.009), but not with the FEV(1)/FVC ratio (r = -0.33; P = 0.35). Changes in HRCT scores between first and last visit were correlated with changes in FEV(1) (r = -0.74; P = 0.02), FVC (r = -0.81; P = 0.007), but not in DL(CO) values (r = 0.07;P = 0.84). At the last visit, of the 10 pts with pulmonary involvement at initial assessment 5 showed worsening of lung involvement and 5 either no significant changes in PFTs and HRCT or mild improvement. PFTs, namely lung volumes, represent a reliable "monitoring" tool in children with JSS to identify pts that need to undergo an HRCT to rule out initial pulmonary involvement and to monitor the course of ILD over time. The weaker clinical value of DL(CO) may relate to poor lung function technique in some younger children.Pediatric Pulmonology 11/2009; 44(12):1226-34. · 2.53 Impact Factor -
Article: Asthma severity according to Global Initiative for Asthma and its determinants: an international study.
[show abstract] [hide abstract]
ABSTRACT: The identification of the factors associated with severe asthma may shed some light on its etiology and on the mechanisms of its development. We aimed to describe asthma severity using the Global Initiative for Asthma (GINA) classification and to investigate its determinants in a cross-sectional, population-based sample in Europe. In the European Community Respiratory Health Survey II (1999-2002), 1,241 adults with asthma were identified. Severity was assessed using the 2002 GINA classification (intermittent, mild persistent, moderate persistent, severe persistent) and it was related to potential determinants by a multinomial logistic model, using the intermittent group as the reference category for relative risk ratios. About 30% of asthmatic subjects were affected by moderate-to-severe asthma. Sensitization to Cladosporium was associated with a more than 5-fold greater risk of having (mild, moderate or severe) persistent asthma than intermittent asthma. Persistent asthma was positively associated with sensitization to house dust mite, nonseasonal asthma, an older age at asthma onset, and chronic cough and phlegm. Sensitization to cat increased the risk of severe asthma only. Smoking was more strongly associated with asthma severity in men, while rhinitis was more strongly associated with asthma severity in women. One third of the asthmatic population have moderate-to-severe asthma. Sensitization to perennial indoor allergens, particularly Cladosporium, is strongly associated with asthma severity. The role of smoking and rhinitis in determining asthma severity may differ between the sexes, and it should be further investigated.International Archives of Allergy and Immunology 09/2009; 151(1):70-9. · 2.40 Impact Factor -
Article: Body mass index, weight gain, and other determinants of lung function decline in adult asthma.
[show abstract] [hide abstract]
ABSTRACT: Little is known about factors associated with lung function decline in asthma. To identify the determinants of FEV(1) decline in adults with asthma with and without airflow obstruction at baseline. An international cohort of 638 subjects with asthma (20-44 years old) was identified in the European Community Respiratory Health Survey (1991-1993) and followed up from 1998 to 2002. Spirometry was performed on both occasions. FEV(1) decline was related to potential determinants evaluated at baseline and during the follow-up by random intercept linear regression models. The analyses were stratified by the presence of airflow obstruction (FEV(1)/forced vital capacity < 0.70) at baseline. In the group of individuals without airflow obstruction (n = 544), a faster FEV(1) decline was observed for subjects with intermediate body mass index (BMI) than for lean and obese subjects. FEV(1) decline was associated with weight gain independently of baseline BMI, and this association was stronger in men (20; 95% CI, 10-30, mL/y/kg gained) than in women (6; 95% CI, 1-11, mL/y). In the group of individuals with airflow obstruction (n = 94), the absence of allergen sensitization and a low BMI at baseline were associated with a faster FEV(1) decline, whereas weight gain was not associated with decline. The detrimental effect of weight gain on FEV(1) decline is particularly relevant in subjects with asthma who still do not have an established airflow obstruction. Our findings support the importance of weight management in asthma and recommend weight loss in overweight or obese individuals with asthma.The Journal of allergy and clinical immunology 04/2009; 123(5):1069-74, 1074.e1-4. · 9.17 Impact Factor -
Article: Rhinitis and onset of asthma: a longitudinal population-based study.
[show abstract] [hide abstract]
ABSTRACT: A close relation between asthma and allergic rhinitis has been reported by several epidemiological and clinical studies. However, the nature of this relation remains unclear. We used the follow-up data from the European Community Respiratory Health Survey to investigate the onset of asthma in patients with allergic and non-allergic rhinitis during an 8.8-year period. We did a longitudinal population-based study, which included 29 centres (14 countries) mostly in western Europe. Frequency of asthma was studied in 6461 participants, aged 20-44 years, without asthma at baseline. Incident asthma was defined as reporting ever having had asthma confirmed by a physician between the two surveys. Atopy was defined as a positive skin-prick test to mites, cat, Alternaria, Cladosporium, grass, birch, Parietaria, olive, or ragweed. Participants were classified into four groups at baseline: controls (no atopy, no rhinitis; n=3163), atopy only (atopy, no rhinitis; n=704), non-allergic rhinitis (rhinitis, no atopy; n=1377), and allergic rhinitis (atopy+rhinitis; n=1217). Cox proportional hazards models were used to study asthma onset in the four groups. The 8.8-year cumulative incidence of asthma was 2.2% (140 events), and was different in the four groups (1.1% (36), 1.9% (13), 3.1% (42), and 4.0% (49), respectively; p<0.0001). After controlling for country, sex, baseline age, body-mass index, forced expiratory volume in 1 s (FEV(1)), log total IgE, family history of asthma, and smoking, the adjusted relative risk for asthma was 1.63 (95% CI 0.82-3.24) for atopy only, 2.71 (1.64-4.46) for non-allergic rhinitis, and 3.53 (2.11-5.91) for allergic rhinitis. Only allergic rhinitis with sensitisation to mite was associated with increased risk of asthma independently of other allergens (2.79 [1.57-4.96]). Rhinitis, even in the absence of atopy, is a powerful predictor of adult-onset asthma.The Lancet 09/2008; 372(9643):1049-57. · 38.28 Impact Factor -
Article: Long-term outcome after pulmonary endarterectomy.
[show abstract] [hide abstract]
ABSTRACT: There are few follow-up studies on long-term cardiopulmonary function after pulmonary endarterectomy (PEA), the operation of choice for chronic thromboembolic pulmonary hypertension (CTEPH). To prospectively evaluate long-term outcome of patients with CTEPH treated with PEA. Between 1994 and 2006, 157 patients (mean age 55 yr) were treated with PEA at Pavia University Hospital. The patients were evaluated before PEA and at 3 months (n = 132), 1 year (n = 110), 2 years (n = 86), 3 years (n = 69), and 4 years (n = 49) afterward by NYHA class, right heart hemodynamic, spirometry, carbon monoxide transfer factor (Tl(CO)), arterial blood gas, and treadmill incremental exercise test. Cumulative survival was 84%. Within 3 months, 18 patients died in-hospital and 2 had lung transplantation; during long-term follow-up, 6 died, 1 had lung transplantation, and 3 had a second PEA (2.5 events per 100 person-years). NYHA class III-IV was the most important predictor of late death, lung transplant, or PEA redo (hazard ratio, 3.94). Extraordinary improvement in NYHA class, hemodynamic, and Pa(O(2)) were achieved in the first 3 months (P < 0.001) and persisted during follow-up; exercise tolerance progressively increased over time (P < 0.001). At 4 years, although 74% of the patients were in NYHA class I and none was in class IV, 24% had pulmonary vascular resistance greater than 500 dyne.s/cm(5) or Pa(O(2)) less than 60 mm Hg; they were significantly older and were more frequently in NYHA class III-IV 3 months after surgery than the others. After PEA, long-term survival and cardiopulmonary function recovery is excellent in most patients.American Journal of Respiratory and Critical Care Medicine 06/2008; 178(4):419-24. · 11.08 Impact Factor -
Article: Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes.
[show abstract] [hide abstract]
ABSTRACT: Early detection of airflow obstruction is particularly important among young adults because they are more likely to benefit from intervention. Using the forced expiratory volume in 1 s (FEV(1)) to forced vital capacity (FVC) (FEV(1)/FVC) <70% fixed ratio, airflow obstruction may be underdiagnosed. The lower limit of normal (LLN), which is statistically defined by the lower fifth percentile of a reference population, is physiologically appropriate but it still needs a clinical validation. To evaluate the characteristics and longitudinal outcomes of subjects misidentified as normal by the fixed ratio with respect to the LLN, 6249 participants (aged 20-44 years) in the European Community Respiratory Health Survey were examined and divided into three groups (absence of airflow obstruction by the LLN and the fixed ratio; presence of airflow obstruction only by the LLN; presence of airflow obstruction by the two criteria) for 1991-1993. LLN equations were obtained from normal non-smoking participants. A set of clinical and functional outcomes was evaluated in 1999-2002. The misidentified subjects were 318 (5.1%); only 45.6% of the subjects with airflow obstruction by the LLN were also identified by the fixed cut-off. At baseline, FEV(1) (107%, 97%, 85%) progressively decreased and bronchial hyperresponsiveness (slope 7.84, 6.32, 5.57) progressively increased across the three groups. During follow-up, misidentified subjects had a significantly higher risk of developing chronic obstructive pulmonary disease and a significantly higher use of health resources (medicines, emergency department visits/hospital admissions) because of breathing problems than subjects without airflow obstruction (p<0.001). Our findings show the importance of using statistically derived spirometric criteria to identify airflow obstruction.Thorax 05/2008; 63(12):1040-5. · 6.84 Impact Factor -
Article: Asthma control in Europe: a real-world evaluation based on an international population-based study.
[show abstract] [hide abstract]
ABSTRACT: Epidemiologic evidence related to asthma control in patients from the general population is scanty. We sought to assess asthma control in several European centers according to the Global Initiative for Asthma (GINA) guidelines and to investigate its determinants. In the European Community Respiratory Health Survey II (1999-2002), 1241 adults with asthma were identified and classified into inhaled corticosteroid (ICS) users and non-ICS users in the last year. Control was assessed in both groups by using the GINA proposal (controlled, partly controlled, and uncontrolled asthma), and it was related to potential determinants. Only 15% (95% CI, 12% to 19%) of subjects who had used ICSs in the last year and 45% (95% CI, 41% to 50%) of non-ICS users had their asthma under control; individuals with uncontrolled asthma accounted for 49% (95% CI, 44% to 53%) and 18% (95% CI, 15% to 21%), respectively. Among ICS users, the prevalence of uncontrolled asthma showed great variability across Europe, ranging from 20% (95% CI, 7% to 41%; Iceland) to 67% (95% CI, 35% to 90%; Italy). Overweight status, chronic cough and phlegm, and sensitization to Cladosporium species were associated with poor control in ICS users. About 65% and 87% of ICS users with uncontrolled and partly controlled asthma, respectively, were on a medication regimen that was less than recommended by the GINA guidelines. Six of 7 European asthmatic adults using ICSs in the last year did not achieve good disease control. The large majority of subjects with poorly controlled asthma were using antiasthma drugs in a suboptimal way. A wide variability in asthma control emerged across Europe. Greater attention should be paid to asthma management and to the implementation of the GINA guidelines.The Journal of allergy and clinical immunology 01/2008; 120(6):1360-7. · 9.17 Impact Factor -
Article: Factors affecting adherence to asthma treatment in an international cohort of young and middle-aged adults.
[show abstract] [hide abstract]
ABSTRACT: A major reason of the poor control of asthma is that patients fail to adhere to their treatment. The aim of the study was to identify factors affecting changes in asthma treatment adherence in an international cohort. A follow-up study was carried out by means of a structured clinical interview in 971 subjects with asthma from 12 countries who participated in both the European Community Respiratory Health Survey: ECRHS-I (1990-94) and ECRHS-II (1998-2002). Subjects were considered adherent if they reported they normally took all the prescribed drugs. A logistic model was used to study the adjusted effect of the determinants. The net change in adherence to anti-asthmatic treatment per 10 years of follow-up was -2% (95% CI: -9.5, 5.5), 7.5% (-2.6, 17.6), 15.0% (6.6, 23.5) and 19.8% (4.1, 35.5), respectively, in Nordic, Mediterranean, Continental and extra-European areas. Among the 428 non-adherent subjects in ECRHS-I, having regular consultations with health care professionals was the strongest predictor of increased adherence (OR 3.32; 95% CI: 1.08-10.17). Among the 543 adherent subjects in ECRHS-I, using inhaled corticosteroids significantly predicted a persistence of adherence (OR 2.04; 95% CI: 1.11-3.75). No effect of gender, age, duration of the disease, smoking habit and educational level was observed. Our findings highlight the key role of doctors and nurses in educating and regularly reviewing the patients and support the efforts for an improvement of clinical communication.Respiratory Medicine 07/2007; 101(6):1363-7. · 2.47 Impact Factor -
Article: Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE.
[show abstract] [hide abstract]
ABSTRACT: Few studies have investigated the long-term association between inhaled corticosteroids (ICSs) and lung function decline in asthma. To evaluate whether prolonged treatment with ICSs is associated with FEV(1) decline in adults with asthma. An international cohort of 667 subjects with asthma (20-44 years old) was identified in the European Community Respiratory Health Survey (1991-1993) and followed up from 1999 to 2002. Spirometry was performed on both occasions. FEV(1) decline was analyzed according to age, sex, height, body mass index, total IgE, time of ICS use, and smoking, while adjusting for potential confounders. As ICS use increased, the decline in FEV(1) was lower (P trend = .025): on average, decline passed from 34 mL/y in nonusers (half of the sample) to 20 mL/y in subjects treated for 48 months or more (18%). When adjusting for all covariates, there was an interaction (P = .02) between ICS use and total IgE: in subjects with high (>100 kU/L) IgE, ICS use for 4 years or more was associated with a lower FEV(1) decline (23 mL/y; 95% CI, 8-38 compared with nonusers). This association was not seen in those with lower IgE. Although confirming a beneficial long-term association between ICSs and lung function in asthma, our study suggests that subjects with high IgE could maximally benefit from a prolonged ICS treatment. This study adds further evidence to the beneficial effect of inhaled steroids on lung function in asthma; future studies will clarify whether calibrating the corticosteroid dose according to the level of total IgE is a feasible approach in asthma management.Journal of Allergy and Clinical Immunology 03/2007; 119(3):611-7. · 11.00 Impact Factor
Top co-authors
Top Journals
Institutions
-
2012
-
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Veneto, Italy
-
-
2006–2012
-
Policlinico San Matteo Pavia Fondazione IRCCS
Pavia, Lombardy, Italy
-
-
2003–2012
-
Università degli studi di Pavia
- Department of Molecular Medicine
Pavia, Lombardy, Italy -
Università degli studi di Verona
- Department of Public Health and Community Medicine
Verona, Veneto, Italy -
Università degli Studi di Genova
- Dipartimento di Medicina sperimentale (DIMES)
Genova, Liguria, Italy
-
